 |
|
Reducing Blockage Fails to Improve Access to the Bloodstream for Kidney Dialysis
May 23, 2008Reducing early blockages in bloodstream access for kidney failure treatment does not increase the likelihood that the access will function adequately for long-term treatments, according to a study funded by the National Institutes of Health. Results were published May 14, 2008, in the Journal of the American Medical Association.
"Since most of the 470,000 Americans with kidney failure depend on hemodialysis for survival, there is a clear and compelling need to evaluate therapies that reduce or prevent access failure," said NIH Director Elias A. Zerhouni, M.D. "These results tell us we need to keep looking for solutions."
Hemodialysis filters waste and extra fluid from the bloodstream and requires a vascular access - a site on the body where blood is removed and returned. Fistulas are the preferred type of access since they clot less often, experience fewer infections, and are less costly; patients with fistulas also have lower mortality. A fistula is created by joining a section of an artery and a vein to make one large vessel capable of handling high volumes of blood during hemodialysis. But maintaining any access site is a major clinical challenge. Blood clotting in the fistula is the most frequent cause of early fistula failure. Clotting, infection and low blood-flow rates in the access site are common reasons for hospitalizations requiring multiple treatments or surgeries. Read about vascular access at http://kidney.niddk.nih.gov/kudiseases/pubs/vascularaccess.
The Dialysis Access Consortium (DAC) found that only 12 percent of patients developed blood clots in the fistula when treated with the clot-preventing drug clopidogrel, compared to nearly 20 percent of patients treated with placebo. Nevertheless, about 60 percent of new fistulas in each group could not be used for long-term dialysis treatments. Complications such as bleeding were similar across the study groups.
DAC studied nearly 900 patients at 9 U.S. medical centers in academic and community practices in urban and rural settings. Participants received a new fistula and took the anti-platelet drug clopidogrel (Plavix) or a placebo tablet daily for 6 weeks to determine if the drug would maintain blood flow in fistulas and increase the number suitable for dialysis.
"Because vascular access is critical for delivering lifesaving care, we are already organizing another multi-center study to look for other ways to improve fistulas," said co-author Catherine M. Meyers, M.D., a kidney specialist in charge of DAC at NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which funded the study.
The DAC Fistula Trial is the largest multi-center trial to look at preventing blood clots in new fistulas and the first to test whether prevention would allow more fistulas to be useable for dialysis. NIDDK has funded DAC since 2000. Clopidogrel and placebo were donated by what is now Sanofi Aventis/Bristol-Myers Squibb.
The National Institute of Diabetes and Digestive and Kidney Diseases, a component of the NIH, conducts and supports research in diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition, and obesity; and kidney, urologic, and hematologic diseases. Spanning the full spectrum of medicine and afflicting people of all ages and ethnic groups, these diseases encompass some of the most common, severe, and disabling conditions affecting Americans. For more information about NIDDK and its programs, see www.niddk.nih.gov.
The National Institutes of Health (NIH) - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
The National Institutes of Health (NIH)
The Dialysis Access Consortium (DAC) found that only 12 percent of patients developed blood clots in the fistula when treated with the clot-preventing drug clopidogrel, compared to nearly 20 percent of patients treated with placebo. Nevertheless, about 60 percent of new fistulas in each group could not be used for long-term dialysis treatments. Complications such as bleeding were similar across the study groups.
DAC studied nearly 900 patients at 9 U.S. medical centers in academic and community practices in urban and rural settings. Participants received a new fistula and took the anti-platelet drug clopidogrel (Plavix) or a placebo tablet daily for 6 weeks to determine if the drug would maintain blood flow in fistulas and increase the number suitable for dialysis.
"Because vascular access is critical for delivering lifesaving care, we are already organizing another multi-center study to look for other ways to improve fistulas," said co-author Catherine M. Meyers, M.D., a kidney specialist in charge of DAC at NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which funded the study.
The DAC Fistula Trial is the largest multi-center trial to look at preventing blood clots in new fistulas and the first to test whether prevention would allow more fistulas to be useable for dialysis. NIDDK has funded DAC since 2000. Clopidogrel and placebo were donated by what is now Sanofi Aventis/Bristol-Myers Squibb.
The National Institute of Diabetes and Digestive and Kidney Diseases, a component of the NIH, conducts and supports research in diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition, and obesity; and kidney, urologic, and hematologic diseases. Spanning the full spectrum of medicine and afflicting people of all ages and ethnic groups, these diseases encompass some of the most common, severe, and disabling conditions affecting Americans. For more information about NIDDK and its programs, see www.niddk.nih.gov.
The National Institutes of Health (NIH) - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
The National Institutes of Health (NIH)
Science News and Science Current Events Tag Cloud
This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size.
Nanocrystals Marine Species White Dwarf Heart Attack Flooding Parkinson's disease Tumors Electronics Inflammation Neurodegenerative Disease Lymphedema Genetic Mutation Neanderthal Uterine Fibroids Drinking Muscular Dystrophy Spectroscopy Ethanol Production Facial Expressions Mortality Penguins Tomato Anemia Drug Resistance Happiness
See More: Science News Tags
Kidney Failure Current Events and Kidney Failure News RSSU finds treatment that significantly slows progression of eye damage in persons with type 1 diabetes
University of Minnesota Medical School researcher Michael Mauer, M.D., has found a treatment that significantly slows the progression of eye injury in people with type 1 diabetes, a common complication caused by this disease.
UT researcher: Interferon alpha can delay full onset of type I diabetes
A low dose of oral interferon alpha shows promise in preserving beta cell function for patients with newly diagnosed type 1 diabetes, or juvenile diabetes.
Novel DNA vaccine leads to kidney damage prevention in systemic lupus erythematosus models
DNA vaccination using lupus autoantigens and interleukin-10 (IL-10, a cytokine that plays an important role in regulating the immune system) has potential as a novel therapy to induce antigen specific tolerance and may help to prevent kidney damage in patients with systemic lupus erythematosus (SLE).
Diabetics' heart attack risk can be reduced, research finds
People with diabetes who maintain intensive, low blood sugar levels are significantly less likely to suffer heart attacks and coronary heart disease, new research published today in The Lancet has shown.
Combination of aspirin and an anti-clotting drug reduces risk of dialysis access failure
For the first time, a combination of aspirin and the anti-platelet drug dipyridamole has been shown to significantly reduce blockages and extend the useful life of new artery-vein access grafts used for hemodialysis, according to a study by the Dialysis Access Consortium (DAC).
Old diabetes drug teaches experts new tricks
Research from the Johns Hopkins Children's Center reveals that the drug most commonly used in type 2 diabetics who don't need insulin works on a much more basic level than once thought, treating persistently elevated blood sugar - the hallmark of type 2 diabetes - by regulating the genes that control its production.
Gene hunters target child kidney failure
Researchers are zeroing in on the genetic abnormalities predisposing to vesicoureteric reflux (VUR), one of the most common causes of urinary tract infections and kidney failure in children, reports a study in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
Study indicates that a common virus could cause high blood pressure
A new study suggests for the first time that cytomegalovirus (CMV), a common viral infection affecting between 60 and 99 percent of adults worldwide, is a cause of high blood pressure, a leading risk factor for heart disease, stroke and kidney disease.
Scripps research scientists discover molecular defect involved in hearing loss
Scientists from The Scripps Research Institute have elucidated the action of a protein, harmonin, which is involved in the mechanics of hearing.
New research confirms milestone study on blood pressure meds
New research supports the findings of a landmark drug comparison study published in 2002 in which a diuretic drug or "water pill" outperformed other medications for high blood pressure. A scientific team including investigators from The University of Texas Health Science Center at Houston reports the findings in the May 11 issue of the Archives of Internal Medicine.
More Kidney Failure Current Events and Kidney Failure News Articles
 |
Kidney Failure: the Facts by J. Stewart Cameron (Author) Guy's and St Thomas' Hospitals, U.K. Practical patient-education text on kidney disease, for patients and their families. Explains in laylanguage the causes and symptoms of kidney failure and the options available for treatment, including dialysis and transplantation. Softcover. |
 |
Beyond The Barriers: Learning To Live with Kidney Failure by Alvieno Stinson (Author) Terrifically written inspirational story about true events! You will enjoy reading about the physical, mental and spiritual journey Alvieno Stinson experiences as he learns to live with kidney failure. If you want to change your Health behavior or the health behavior of any man with a chronic disease like Kidney failure, prostate cancer, diabetes or Heart disease this book is a MUST READ! "Beyond The Barriers Learning to Live with Kidney Failure" is destined to be #1 on the New York Times Best Sellers list! "I read your book over and over again because it inspires me so Much!" says Pamela Johnson, owner and operator of Bronzeville's 1st Bed and Breakfast, Chicago Illinois. "AMAZING!" says Dr. Dennis Kimbro, author of Think and Grow Rich A Black Choise and Daily Motivations for African... |
 |
Caring for a cat with kidney failure by Cat Professional Ltd Caring for a cat with kidney failure has been written as an information source and support tool primarily aimed at cat owners whose cats have been diagnosed with kidney failure. It is also designed to be a resource for student vets, veterinary nurses and technicians. The science and emotional aspects of dealing with a diagnosis of kidney failure are addressed. The book is 58 pages long and includes colour photographs illustrating different clinical signs (symptoms) of kidney failure, diagnostic tests and treatments such as a step by step guide to safely and successfully giving pills to a cat. The book explains what a diagnosis of kidney failure means and how best to treat this. A case study is included to show how treatment can be successful and there is a glossary of terms used by vets.... |
 |
FlameEz-Kidney, 60 Capsules/Bottle by FlameEz Healthy kidneys help regulate the body's water and other chemicals in the blood, release hormones to help regulate blood pressure, make red blood cells and promote strong bones. Chronic kidney disease (CKD) is a progressive loss of renal function over years. It's often silent until the late stages when it can be too late to head off kidney failure. The majority of people with CKD have evidence of chronic inflammation. CKD and kidney dysfunction cause accumulation of toxins and increased oxidative stress, which prime inflammatory cells, leading to increased release of reactive oxygen species, destructive proteases and inflammatory mediators. Chronic inflammation in CKD may also lead to accelerated cardiovascular risk, the main cause of death in CKD and end stage renal disease. Evidence... |
 |
Living Well with Kidney Failure: A Guide to Living Your Life to the Full (Class Health) by Juliet Auer (Author), Richenda Milton-Thompson (Editor), David Woodroffe (Editor) This practical and inspiring book will give you the confidence to live a full and rewarding life. It highlights the experiences of a number of very different people, from all walks of life, ages and family situations. These shared personal accounts celebrate the fullness of life that people living with kidney failure can, and do, achieve. |
 |
Eating Well with Kidney Failure by Helena Jackson (Author) |
 |
Feline Kidney Solution II by Healthy Pet Solutions Kidney Solution II for Cats is a natural herbal supplement with anti-oxidants, cellular cleansing and cellular energy enhancing activities. It supports healthy feline kidney function that is important for proper kidney filtrations and protection from toxic damage. |
 |
You Have the Power to Prevent Kidney Disease: A Health Education Video [For People with Diabetes, High Blood Pressure, Family Member with Kidney Failure Also With: National Kidney Disease Education Program (Producer) You Have the Power to Prevent Kidney Disease: A Health Education Video [For People with Diabetes, High Blood Pressure, Family Member with Kidney Failure. Can be used in dialysis centers, doctor's offices, and health fairs. |
 |
Strength and Compassion in Kidney Failure: Writings of Mildred (Barry) Friedman Professional Kidney Patient by Springer Written from the perspective of the joy of celebrating life rather than lamenting the scourge of chronic illness, this collection of medical columns, short stories, and letters recounts the wonderful and upbeat tale of coping, surviving, and prevailing. Starting out as a medical technician, wife, and mother faced with progressive loss of sight and ambulation, Barry Friedman devised strategies for using her intellect to benefit other patients and medical professionals. Free from self pity and permeated by hope, enthusiasm, and the belief that there was much to be accomplished, Friedman proved to be a keen observer of the sense and nonsense comprising her therapeutic regimen for diabetes, Addison's disease, and renal failure. Especially helpful are Friedman's hints for dealing... |
 |
60 Minutes - A Thousand Lives a Month (February 17, 2008) Airdate: 02/17/08 Trasylol is a surgical drug designed to control bleeding in complex heart surgery, and on that score, it did its job well. But Trasylol has also been linked to the deaths of many patients by causing kidney failure. Could thousand of lives have been saved if the FDA and Bayer Corporation had acted earlier on Trasylol? Scott Pelley investigates. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
| © 2009 BrightSurf.com |